|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
1997-12-12
|
|
pubmed:abstractText |
Phosphodiesterase III (PDE3) inhibitors are inotropic agents used to treat congestive heart failure (CHF) and are less effective in patients with severe CHF. Little is known about relative changes in PDE3 activity or gene expression during the evolution of cardiomyopathy.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0009-7322
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
4
|
|
pubmed:volume |
96
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3116-23
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9386183-3',5'-Cyclic-AMP Phosphodiesterases,
pubmed-meshheading:9386183-Animals,
pubmed-meshheading:9386183-Blotting, Northern,
pubmed-meshheading:9386183-Cardiac Pacing, Artificial,
pubmed-meshheading:9386183-Cardiomyopathy, Dilated,
pubmed-meshheading:9386183-Dogs,
pubmed-meshheading:9386183-Down-Regulation,
pubmed-meshheading:9386183-Gene Expression Regulation, Enzymologic,
pubmed-meshheading:9386183-Glyceraldehyde-3-Phosphate Dehydrogenases,
pubmed-meshheading:9386183-Heart Failure,
pubmed-meshheading:9386183-Milrinone,
pubmed-meshheading:9386183-Myocardium,
pubmed-meshheading:9386183-Pyridones
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
Development of decompensated dilated cardiomyopathy is associated with decreased gene expression and activity of the milrinone-sensitive cAMP phosphodiesterase PDE3A.
|
|
pubmed:affiliation |
Department of Pathology, New York Medical College, Valhalla 10595, USA. carolyn_smith@nymc.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
